CN1791374A - Nipple device - Google Patents

Abstract

A nipple device (10) has a nipple (11), and a nipple holder (15) for holding the nipple (11). The nipple holder (15) is internally provided with a liquid-permeable body (25) and has a cap (17) mounted thereon. A medicine container (20) covered by a film (21) is received in the cap (17). When the cap (17) is mounted on the nipple holder (15), a projection (19) on the nipple holder (15) pricks the film (21).

Description

Pacifier device

technical field

The present invention relates to a pacifier device capable of feeding medicine to infants.

Background technique

Conventionally, there has been known a pacifier filled with a drug to be licked by an infant as a pacifier for administering medicine while licking it (for example, refer to Japanese Patent Application Publication No. 2001-511644).

The pacifier that the baby licks has a mouthpiece, and the tablet is arranged in the empty space of the mouthpiece. The tablet is administered to the infant by holding the mouthpiece in the infant's mouth.

Although in the pacifier licked by the baby of the above prior art, the tablet is arranged in the space of the mouthpiece, when the tablet is replenished to the pacifier licked by the baby, the tablet must be arranged in the vacancy of the mouthpiece. is complicated.

In addition, although it is necessary to regularly clean the pacifier that the baby licks, the container cleaning operation cannot be performed because the pacifier that the baby licks is integrally formed.

Contents of the invention

The present invention was made in consideration of such a problem, and an object of the present invention is to provide a teat device that can easily replenish and clean medicines.

The pacifier device of the present invention is equipped with: a pacifier, a pacifier holding body for holding the pacifier, and a cover engaged with the pacifier holding body; a medicine container portion is provided in the cover, and the medicine is filled therein, and one side of the pacifier is covered with Covered by a film; a rupture part is provided on the pacifier holder, and the film is pierced when the cover is engaged on the pacifier holder.

The pacifier device of the present invention is characterized in that the pacifier holder is provided with a liquid-permeable body extending into the pacifier, and the rupture portion of the pacifier holder is constituted by a protrusion piercing the film.

The pacifier device of the present invention is characterized in that the pacifier holder is provided with external threads, and the cap is provided with internal threads engaged with the external threads.

The pacifier device of the present invention is characterized in that the liquid permeable body is composed of a plate-shaped body abutting against the film of the drug container portion, and a rod-shaped body extending from the plate-shaped body toward the pacifier.

The pacifier device of the present invention is characterized in that an opening is provided in the plate-shaped body of the liquid-permeable body, and the protrusion protrudes from the pacifier side to the drug container side through the opening.

The pacifier device of the present invention is characterized in that the medicine container part is constituted by a medicine container provided in the cap.

The pacifier device of the present invention is characterized in that the medicine container portion is constituted by a region in the cap defined by a thin film.

The pacifier device of the present invention is characterized in that the pacifier holder has a communication space communicating with the inside of the pacifier, and the communication space is provided on the medicine container side and is covered by a partition wall having a communication port.

The pacifier device of the present invention is characterized in that the rupture portion of the pacifier holder is constituted by an end portion of the partition wall.

The pacifier device of the present invention is characterized in that a check valve for allowing the medicine to flow from the medicine container portion to the pacifier holder is provided on the opening of the partition wall.

The pacifier device of the present invention is characterized in that it is equipped with: a pacifier, a pacifier holding body that holds the pacifier and has a container accommodating portion communicated with one side of the pacifier, and a cover that is swingably mounted on the pacifier holding body and covers the container accommodating portion, A drug container is arranged in the container housing portion, and the drug container is filled therein, and has an opening on the nipple side.

The pacifier device of the present invention is characterized in that a cylindrical guide protruding toward the pacifier is provided on the container accommodating portion, and the medicine container has a discharge port inserted into the cylindrical guide.

The pacifier device of the present invention is characterized in that the drug container can be freely removed from the container accommodating portion, and the lid is provided with engaging ribs to engage with the cylindrical guide of the container accommodating portion.

The pacifier device of the present invention is characterized in that the drug container is made of soft material and is fixed in the container accommodating portion, and the cap is provided with a squeezing portion for squeezing the drug container.

The teat device of the present invention is characterized in that the drug contains a xylitol component.

The teat device of the present invention is characterized in that the medicine contains a virus capturing composition.

The teat device of the present invention is characterized in that the virus trapping composition contains a water extract of bird's nest and/or an enzyme-treated bird's nest as an active ingredient.

Description of drawings

Fig. 1 is a side sectional view showing a first embodiment of a pacifier device according to the present invention.

Figure 2 is an exploded view of the teat assembly.

Fig. 3 is a view taken along line III in Fig. 1 .

Fig. 4 is a side sectional view showing a second embodiment of the teat device according to the present invention.

Figure 5 is an exploded view of the teat assembly.

Fig. 6 is a side sectional view showing a third embodiment of the teat device according to the present invention.

Fig. 7 is a partial sectional view of the teat device.

Fig. 8 is a diagram showing a modified example of the teat device according to the present invention.

Fig. 9 is a diagram showing a modified example of the teat device according to the present invention.

Fig. 10 is a graph showing the results of examining the influenza virus infection-neutralizing activity of virus-trapping compositions.

Fig. 11 is a graph showing the results of investigation on the types and contents of sialic acid molecules contained in virus capture compositions.

Fig. 12 is a graph showing the results of investigating the binding properties of glycopeptides contained in virus capture compositions separated by SDS-PAGE to influenza virus.

Detailed ways

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

1 to 3 are diagrams showing a first embodiment of a teat device according to the present invention. Wherein, FIG. 3 is a view from the direction of line III in FIG. 1 .

As shown in Fig. 1 to Fig. 3, the pacifier device 10 is provided with a pacifier 11 which is contained in the mouth of a baby, a pacifier holder 15 for holding the pacifier 11, a liquid permeable body 25 extending from the pacifier holder 15 into the pacifier 11, And the cover 17 engaged on the nipple holder 15 .

Inside the cover 17, a medicine container (medicine container part) 20 filled with a liquid medicine, for example, a liquid medicine containing a xylitol component for preventing dental caries is provided. The nipple 11 side of this medicine container part 20 is Silver paper or resin film 21 covers. The nipple holder 15 is provided with a protrusion 19 that penetrates the film 21 of the drug container 20 when the lid 17 is engaged with the nipple holder 15 . Such protrusions 19 function as rupture portions that rupture the film 21 when the cap 17 is engaged with the nipple holder 15 .

Next, the constituent parts of each part will be described in more detail. First, the teat 11 includes a cylindrical teat main body 11 a and a plate-shaped base end portion 11 b provided at the base end of the teat main body 11 . An opening 12 is provided in the nipple main body 11a, and the medicine sent through the liquid-permeable body 25 is supplied to the outside.

Furthermore, the teat holder 15 includes a cylindrical portion 15a and a large diameter portion 15b having a larger diameter than the cylindrical portion 15a. The base end portion 11b of the teat 11 is inserted and fixed into the large diameter portion 15b of the teat holder 15, and the holding frame 13 is fitted into the large diameter portion 15b from the outside of the base end portion 11b. In this way, the teat 11 is held by the teat holder 15 .

In addition, the medicine container 20 enters into the cylindrical portion 15 a of the nipple holder 15 , and the medicine container 20 is joined to the cap 17 .

The nipple 11 side of the drug container 20 is covered with the film 21 as described above, and the thin film 21 is easily pierced by the protrusion 20 of the nipple holder 15 to be damaged.

In addition, the liquid-permeable body 25 includes a disc-shaped plate-shaped body 25b having the same shape as the film 21 of the drug container 20 and abutting on the film 21, and a plate-shaped body 25b extending from the plate-shaped body 25b toward the teat 11 side. rod-shaped body 25a. The liquid-permeable body 25 is made of a sponge material as a whole, and allows the medicine in the medicine container 20 to pass through toward the teat 11 side.

In addition, an opening 26 located below the rod-shaped body 25 a is formed in the plate-shaped body 25 b of the liquid-permeable body 25 . By inserting the protrusion 19 for fixing the nipple holder 15 into the opening 26 of the plate-like body 25 b, the liquid permeable body 25 can be positioned and fixed by the nipple holder 15 .

In addition, the rod-shaped body 25a of the liquid-permeable body 25 preferably has the same outer shape as the inner surface of the nipple body 11a of the nipple 11, and in this case, the liquid-permeable body 25 can be positioned and fixed by the nipple body 11a.

Furthermore, the protrusion 19 of the nipple holder 15 is held between the cylindrical portion 15a and the large-diameter portion 15b, and the front end of the medicine container 20 on the film 21 side is tapered.

In addition, an external thread 16 is provided on the outer surface of the cylindrical portion 15 a of the nipple holder 15 , and an internal thread 18 engaged with the external thread 16 is provided on the inner surface of the cap 17 . However, it is also possible to engage the cylindrical portion 15a and the cover 17 by simply inserting instead of snap-fitting.

In any case, the cylindrical portion 15a of the nipple holder 15 is engaged with the lid 17 in a sealed state.

Next, the operation of the present embodiment having such a configuration will be described.

First, as shown in FIG. 2 , the protrusion 19 of the nipple holder 15 is inserted into the opening 26 of the plate-shaped body 25 b fixed to the liquid permeable body 25 .

Next, the base end portion 11b of the teat 11 is fitted into the large diameter portion 15b of the teat holder 15, and the holding frame 13 is further fitted into the large diameter portion 15b, so that the teat 11 is held by the teat holder 15.

In this case, it is preferable to interpose a seal between the large-diameter portion 15 b of the teat holder 15 and the holder frame 13 . In addition, since the protrusion 19 of the nipple holder 15 is inserted and fixed in the opening 26 of the liquid-permeable body 25, and the rod-shaped body 25a of the liquid-permeable body 25 abuts against the inner surface of the nipple main body 11a, the liquid-permeable body 25 is close to the nipple. The holding body 15 and the nipple 11 are fixed in position.

Next, the internal thread 18 of the cap 17 is engaged with the external thread 16 of the pacifier holder 15 , and the cap 17 is fitted over the cylindrical portion 15 a of the pacifier holder 15 . In this case, in the cover 17, the medicine container 20 is installed in advance by an adhesive, and when the cover 17 is put on the cylindrical portion 15a of the teat holder 15, the film 21 of the medicine container 20 is covered by the teat holder 15. The protrusion 19 is pierced and damaged.

When the film 21 is damaged, the liquid medicine (including the xylitol component) in the medicine container 20 is transferred to the teat 11 side through the liquid-permeable body 25 .

If the baby sucks the nipple 11, the medicine transferred from the liquid-permeable body 25 to the nipple 11 enters the mouth of the baby from the opening 12 of the nipple body 11a, and the xylitol component can prevent dental caries.

Furthermore, when all the medicine in the medicine container 20 is consumed, the cap 17 and the medicine container 20 are removed from the nipple holder 15, and a new lid 17 having the medicine container 20 filled with medicine in advance is attached to the nipple holder 15.

In addition, after using the pacifier device 10 for a long time, each component can be cleaned by disassembling each component in the opposite way to the above (refer to FIG. 2 ).

As described above, according to the present embodiment, when the medicine in the medicine container 20 is consumed, only by installing a new medicine container 20 and the cap 17 on the nipple holder 15, it is possible to easily and simply carry out medicine refilling. Replenish. In addition, each component can be easily cleaned just by disassembling each component.

Next, a second embodiment of the pacifier device according to the present invention will be described with reference to FIGS. 4 and 5 . In addition, in the second embodiment shown in FIGS. 4 and 5 , the same parts as those in the first embodiment shown in FIGS. 1 to 3 are given the same reference numerals, and detailed descriptions are omitted.

As shown in FIGS. 4 and 5 , the pacifier device 10 includes a pacifier 11 for sucking in the mouth of an infant, a pacifier holder 15 for holding the pacifier 11 , and a cover 17 engaged with the pacifier holder 15 .

A membrane is provided inside the cover 17 . And the region 30 separated by the film 21 in the cover 17 is filled with a liquid medicament, such as a liquid medicament added with an anti-caries xylitol component. In this case, the region 30 in the cover 17 delimited by the membrane 21 forms the medicament container.

In addition, when the cap 17 is engaged with the teat holder 15, the film 21 is damaged by an end portion (broken portion) 15d of the partition wall 15c of the teat holder 15 described later.

However, the nipple holder 15 includes a cylindrical portion 15a and a large-diameter large-diameter portion 15b provided on one side of the cylindrical portion 15a, and the aforementioned partition wall 15c is provided on the other side of the cylindrical portion 15a.

The pacifier holder 15 having such a structure has a communication space 33 communicating with the inside of the pacifier 11 inside, and the communication space 33 is covered by the above-mentioned partition wall 15c. Furthermore, a communication port 31 is provided in the partition wall 15c, and a check valve 32 for freely opening and closing the communication port 31 is attached to the surface of the partition wall 15c on the side of the communication space 33 . The one-way valve 32 allows the medicine in the area 30 to flow into the communication space 33 , and the medicine in the communication space 33 cannot transfer to the area 30 side.

Next, the operation of the present embodiment having such a configuration will be described.

First, as shown in FIG. 4, the base end portion 1b of the teat 11 is inserted into the large diameter portion 15b of the teat holder 15, and then the holding frame 13 is inserted into the large diameter portion 15b, and the teat 11 is held by the teat holder 15. .

Next, the internal thread 18 of the cap 17 is engaged with the external thread 16 of the pacifier holder 15 , and the cap 17 is inserted into the cylindrical portion 15 a of the pacifier holder 15 . In this case, the area 30 divided by the film 21 in the cover 17 is filled with medicine in advance. The end portion 15d of the partition wall 15c of the body 15 is damaged.

If the film 21 is damaged, the medicine in the area 30 will flow into the communication space 33 of the nipple holder 15 through the communication port 31 and the one-way valve 32, and then the medicine in the communication space 33 will transfer to the nipple 11 side.

If the baby sucks the nipple 11, the medicine transferred to the nipple 11 enters the mouth of the baby through the opening 12, and the xylitol component can prevent dental caries.

Furthermore, when all the medicine in the region 30 of the cap 17 is consumed, the cap 17 is removed from the nipple holder 15, and a new cap 17 filled with medicine in advance is attached to the nipple holder 15.

In addition, after using the pacifier device 10 for a long time, each component can be cleaned by disassembling each component in the opposite way to the above (refer to FIG. 5 ).

As described above, according to the present embodiment, when the medicine is consumed, the work of replenishing the medicine can be easily and simply performed, and the cleaning of each component can be easily performed.

Next, a third embodiment of the teat device according to the present invention will be described with reference to FIGS. 6 to 9 .

As shown in Fig. 6 and Fig. 7, the pacifier device 10 is provided with the pacifier 11 that the infant sucks in the mouth, holds the pacifier 11 and has the pacifier holding body 15 that communicates with the container accommodating portion 43 on one side of the pacifier 11, and a freely swingable The lid 42 is attached to the nipple holder 15 and covers the container accommodating portion 43 .

Among them, the nipple 11 is hollow, and as described later, a liquid drug filled in the drug container 45 , for example, a drug containing xylitol component for preventing dental caries, is fed and stored therein. In addition, the nipple 11 is provided with an opening 12 for supplying the drug stored inside to the outside.

The pacifier holder 15 includes a flange 40 for holding the pacifier 11 , and a flange cover 41 provided on the flange 40 , and a container accommodating portion 43 is provided in the flange cover 41 .

The container accommodating part 43 provided in the flange cover 41 is opened upward, and the medicine container 45 filled with the liquid medicine is accommodated in this container accommodating part 43 . In addition, a cylindrical guide 44 protruding toward the teat 11 side is provided on the container housing portion 43 , and the container housing portion 43 communicates with the teat 11 side through the cylindrical guide 44 .

However, the cover 42 is swingably attached to the flange cover 41 of the nipple holder 15 via a swing shaft 42a, and covers the container accommodating portion 43 from above. Furthermore, an engaging rib 48 engaged with the upper end portion of the cylinder guide 44 is provided on the inner surface of the cover 42 . Furthermore, when the container accommodating portion 43 is covered by the lid 42 , the engaging rib 48 is inserted into the container accommodating portion 43 and engaged with the upper end portion of the cylinder guide 44 .

In this case, the upper end portion of the cylindrical guide 44 has a tapered shape tapered downward, and the front end 48a of the engaging rib 48 has a tapered downward shape corresponding to the upper end portion of the cylindrical guide 44 . conical. In addition, the engaging rib 48 is preferably made of a soft material.

In addition, a liquid drug is filled in the drug container 45 and is detachably accommodated in the container accommodating portion 43 . That is, the drug container 45 is made of a soft material as a whole, and includes a container body 45a for storing drugs, and a discharge port 46 made of a hard material provided at the lower end of the container body 45a. The outlet 46 of the drug container 45 is formed with an external thread 46a on its outer surface, and the cylindrical guide fixed to the nipple holder 15 is inserted into the external thread 46a by screwing the internal thread (not shown) of the cylindrical guide 44 into the external thread 46a. Within 44.

Furthermore, it is also possible to fit the discharge port 46 into the cylinder guide 44 without forming external threads on the outer surface of the discharge port 46 .

In FIGS. 6 and 7 , the cover 47 screwed on the discharge port 46 of the drug container 45 is first removed in use, and the drug container 45 is accommodated in the container accommodating portion 43 of the nipple holder 15 . At this time, by screwing the external thread 46a of the discharge port 46 of the chemical container 45 into the internal thread of the cylindrical guide 45, the chemical container 45 can be firmly fixed in the container housing portion 43.

Next, the container body 45 a made of soft material of the drug container 45 is pushed upward, and the drug in the container body 45 a is supplied to the teat 11 side through the discharge port 46 and the cylindrical guide 44 . Then, the drug container 45 is removed from the container housing portion 43 , the lid 42 is swung via the swing shaft 42 a, and the container housing portion 43 is sealed by the lid 42 . At this time, the engaging rib 48 provided on the inner surface of the cover 42 is engaged with the upper end of the cylindrical guide 44 to completely seal the upper end of the cylindrical guide 44 .

Since the engaging rib 48 is formed of a soft material as a whole, the upper end portion of the cylindrical guide 44 can be reliably sealed by the front end 48 a of the engaging rib 48 .

If the baby sucks the nipple 11, the medicine in the nipple 11 enters the mouth of the baby from the opening 12 of the nipple 11, and the xylitol component can prevent dental caries.

Next, modifications of the embodiment shown in FIGS. 6 and 7 will be described with reference to FIGS. 8 and 9 . In the embodiment shown in FIGS. 8 and 9 , the drug container 45 is fixed to the container accommodating portion 43 .

In FIGS. 8 and 9 , the same reference numerals are assigned to the same parts as those in the embodiment shown in FIGS. 6 and 7 , and detailed descriptions will be omitted.

As shown in FIG. 8, the medicine container 45 includes a flexible tube-shaped container body 45a filled with a drug, and a discharge port 46 provided on the lower end portion of the container body 45a.

In addition, the teat holder 15 holding the teat 11 includes a flange 40 and a container housing portion 43 provided on the flange 40 .

The container accommodating portion 43 accommodates the drug container 45 therein, and a cylindrical guide 44 protruding toward the teat 11 side is provided at a lower portion of the container accommodating portion 43 .

Furthermore, the container accommodating part 43 is opened upward, and the cover 42 which covers the accommodating part 43 is swingably attached to the container accommodating part 43 . Furthermore, a pressing portion 49 that presses the bellows-shaped container body 45 a is provided inside the lid 42 .

In FIG. 8 , the drug container 45 is accommodated in the container housing portion 43 of the nipple holder 15 , and the discharge port 46 of the drug container 45 is inserted into the cylindrical guide 44 .

At this time, by forming an external thread on the outside of the discharge port 46 of the medicine container 35 and forming a female thread on the inner surface of the cylinder guide 44, the discharge port 46 can be screwed into the cylinder guide 44 to place the medicine container. 45 is firmly fixed to the container accommodating portion 43.

Next, the lid 42 is swung to cover the container accommodating portion 43 with the lid 42 . At this time, the container body 45a of the drug container 45 is pushed by the pressing portion 49 of the cap 42, and the drug in the container body 45a is delivered to the teat 11 side through the discharge port 46 and the cylindrical guide 44.

Next, another modified example of the present invention will be described with reference to FIG. 9 . In the modified example shown in FIG. 9 , the drug container 45 includes a container body 45 a filled with the drug, and a discharge port 46 provided on the lower end portion of the container body 45 . At this time, the container main body 45a is not in the shape of a bellows, but has a thin shape and is made of a soft material.

In FIG. 9 , the drug container 4 a is accommodated in the container accommodating portion 43 of the nipple holder 15 . At this time, an external thread is formed on the discharge port 46 of the drug container 45 , a female thread is formed on the cylinder guide 44 , and the discharge port 46 is screwed into the cylinder guide 44 .

Next, the lid 42 is swung to cover the container accommodating portion 43 with the lid 42 . The container main body 45 a of the medicine container 45 is pressed by the pressing part 49 . Thereby, the medicine in the container main body 45 a can be delivered to the teat 11 side through the discharge port 46 and the cylinder guide 44 .

Next, a fourth embodiment of the pacifier device according to the present invention will be described with reference to FIGS. 10 to 12 .

The embodiment shown in FIGS. 10 to 12 is different in that a drug containing a virus-capturing composition is used instead of a drug containing a xylitol component as a liquid drug. Others are different from those shown in FIGS. 1 to 9 . Embodiments are substantially the same.

That is to say, in the medicament container 20 shown in Fig. 1 to Fig. 3, replace the medicament containing the xylitol component and be filled with the medicament containing the virus capturing composition, the cover 17 shown in Fig. 4 and Fig. 5 In the area 30 of the xylitol component, instead of the medicine containing the xylitol component, the medicine containing the virus capture composition is filled. Furthermore, in the medicine container 45 shown in FIGS. 6 to 9 , a medicine containing a virus-capturing composition is filled instead of a medicine containing a xylitol component.

Next, this virus capture composition will be described in detail. The virus trapping composition contains a water extract of bird's nest and/or an enzyme-treated product of bird's nest as an active ingredient.

Among them, bird's nest is a nest made by swiftlets that make their own saliva into filaments. In addition to being eaten as a high-end food since ancient times in China, it is also used as a medical function such as clearing the lungs, strengthening the stomach, eliminating phlegm, nourishing the face, and nourishing and strengthening. for food. In addition, as its components, it contains a lot of protein and sugar, and it contains almost no fat.

Among the bird's nests sold in the general market, although there are natural bird's nests picked in caves (cave bird's nest) and indoor cultured (domestic bird's nest), both can be used. In addition, although after removing dirt such as feathers and bird droppings from the picked bird's nest and washing it, the fragments of the collected bird's nest are repeatedly bleached and washed until there are various types of shaped ones, but it is best to use them without excessive washing in the pretreatment Or bleached bird's nest.

The bird's nest water extract of the present invention can be obtained as follows, for example. Add 10 to 1000 times the mass of water to the bird’s nest crushed to a particle size of less than 2 mm, preferably less than 150 μm, and stand or stir at 1 to 100 ° C for 0.5 to 48 hours for extraction, then filter And obtain filtrate. This filtrate can be used as the virus capture composition of the present invention as it is, or it can be suitably concentrated to obtain a concentrated solution. In addition, these can also be powderized by freeze-drying or spray-drying.

In addition, the enzyme-treated bird's nest can be obtained by adding water or hot water in an amount of 10 to 1000 times its mass to the bird's nest crushed into the same size as above, and extracting the same extract as above (the solution before filtration). ), obtained by heat-treating the above-mentioned extract at 60-130° C. for 5-30 minutes after enzyme treatment, and then filtering the above-mentioned extract, or performing enzyme treatment.

As the above-mentioned enzyme, protease is preferable, and generally, for example, one or more kinds of enzymes can be used in combination and are marketed as enzymes for food. Specifically, "pancreatin preparation F" (trade name, manufactured by Amano Pharmaceutical Co., Ltd.), "Aroyase AP-10" (trade name, manufactured by YAKULT Pharmaceutical Industry), "soluble papain" (trade name , manufactured by YAKULT Pharmaceutical Industry), "Heat-resistant protease, サモア一ゼ" (trade name, manufactured by Yamato Kasei), etc.

In addition, the enzyme treatment conditions are not particularly limited, the pH of the solution is adjusted to the optimum pH of the enzyme used, an appropriate amount of enzyme is added, and after reacting at the optimum temperature of the enzyme for 0.5 to 24 hours, heat treatment or the like is performed to inactivate the enzyme. OK. A filtrate obtained by filtering such a reaction liquid as it is or a concentrated liquid obtained by appropriately concentrating can be used as the virus capture composition of the present invention. In addition, these can also be powderized by freeze-drying or spray-drying.

The average molecular weight of the enzyme-treated product is preferably from 5 million to 200,000, more preferably from 2,000 to 70,000.

The virus-capturing composition of the present invention may contain functional food materials such as various sugars, lactic acid bacteria, two-tailed bacteria, polyphenols, and oligosaccharides, protein , fatty acids, minerals, vitamins, dietary fiber, saccharin, surfactants, preservatives and other ingredients.

Although the form of the virus capture agent of the present invention is not particularly limited, it is preferably a solution or a paste. In addition, since the virus-trapping composition is a food-derived component, it has high stability and can be directly administered to the human body as an inhalant or the like.

The content of the water extract of bird's nest and/or the enzyme-treated product of bird's nest in the virus trapping composition of the present invention is preferably 0.1-10000 μg/mL, more preferably 0.2-400 μg/mL.

Each sample shown in Table 1 was prepared and used for the following test.

Table 1 sample grade Approach Sialic acid content (total amount) protein content 1 premium product After protease treatment (37°C, 16 hours), heat (90°C) inactivation. After filtration, it was freeze-dried. 7.6% by mass 64.4% by mass 2 first grade After protease treatment (37°C, 16 hours), heat (90°C) inactivation. After filtration, it was freeze-dried. 4.2% by mass 67.8% by mass 3 Secondary product After soaking in water, boil it, then treat it with protease (37°C, 16 hours), and heat (90°C) to inactivate it. After filtration, it was freeze-dried. 9.6% by mass 46.0% by mass 4 premium product After crushing, sieve (150μm mesh) without protease treatment 5.0% by mass - 5 premium product After crushing, sieve (150μm mesh) without protease treatment 9.5% by mass -

(1) Infection neutralization test

Determination of cell membrane damage caused by human influenza virus by measuring the activity of lactate dehydratase (LDH) released from MDCK (Madian-Darby Canine Kidney) monolayer cells infected with influenza virus (see C-T Guo, C-H Wong, T Kajimoto, T Miura, Y Ida, L R Juneja, M J Kim, H Masuda, T Suzuki, and Y Suzuki. Synthetic sialylphosphatidyl-ethanolamine derivatives bind to human influenza A viruses and inhibit viral infection. Glycoconjugate9 8, J. 15(11):1099-1108).

That is to say, influenza virus (A/PR/8/34(H1N1) or A/Aichi/2/68(H3N2) )), and the EMEN medium (Eagles MinimumEssential Medium) of each sample (final concentration 1～5000μg/mL) shown in Table 1 was inoculated on the MDCK cell of monolayer culture on the 96-well titer plate (flat bottom), in Incubate at 34.5°C for 5 hours.

After culturing, the liquid was removed and suspended in 100 µL of the culture medium. Further, after culturing at 34.5°C for 20 hours, 12.5 μL of the obtained culture solution was diluted to 4 times with 100 mM trihydrochloride buffer (pH 8.2), and 50 μL of the reaction solution (2 mM NAD, 200 m-unit/mL of Diaphorase, 190 mM lithium lactate, 0.78 mM blue tetrazolium, 100 mM Tris-HCl buffer (pH 8.2)). After incubation at 37°C for 10 minutes, the reaction was stopped by adding 100 μL of 0.5M hydrochloric acid. The LDB activity was determined by measuring the absorbance at 550 nm (compared to 630 nm). Furthermore, Fetuin was used as a positive control. Fetuin is a component contained in fetal bovine serum and is known to have influenza virus neutralizing activity. The results are shown in Fig. 10 .

As shown in Figure 10 (A), (B), the IC for the human influenza virus (A/PR/8/34 (H1N1) and A/Aichi/2/68 (H3N2)) of sample 1 ₅₀ was 80 μg/mL, and it was found that the inhibitory activity was 2 to 8 times stronger than that of fetuin as a positive control. On the other hand, it was found that sample 2 had almost the same inhibitory activity as fetuin against human influenza virus (A/PR/8/34/(H1N1)).

Furthermore, with respect to each of the above samples, use NDCK monolayer cells to place the EMEM medium containing bird's nest solution (initial concentration 5 mg/mL) diluted twice each time on a 96-well titer plate (flat bottom). layer cultured MDCK cells were added and cultured at 37°C for 25 hours, and by measuring the activity of lactate dehydratase (LDH) in the obtained culture solution to investigate whether there was cytotoxicity, it was not harmful to MDCK cells in all samples. Cytotoxicity was exhibited, and cases of high safety were identified.

(2) red blood cell anticoagulation test

Inject μL of PBS 25 minutes each time on each concave part of the 96-well titration plate (U bottom), put 25 μL of the solution of the test sample (sample 1, 2) into the first row of the titration plate, and perform several experiments with a micropipette. inhale and exhale. Transfer 25 μL of the well in the first row to the second row, and use a micropipette to aspirate and discharge several times. The same operation was performed for the third and fourth columns to prepare a 2-fold dilution column.

After each dispensing of 25 μL of the solutions containing the viruses shown in Table 2 into each well, the titer plate was shaken slowly, and then left at 4° C. for 60 minutes. Then, 50 μL of 0.5% (V/V) human erythrocyte suspension was dispensed each time on each well, the titration plate was shaken slowly, and then left at 4° C. for 60 minutes, and the red blood cells settled on the bottom of each well. Determine the presence or absence of coagulation in the state, and calculate the minimum concentration of each sample due to the occurrence of coagulation inhibition. The results are shown in Table 2.

Table 2 Virus Anticoagulant concentration of red blood cells (mg/L) Sample 1 Sample 2 A/PR/8/34(H1N1) 2.5 40 A/Aichi/2/68(H3N2) 20 640 A/Hong Kong/1/68(H3N2) 10 40 A/Memphis/1/71(H3N2) 20 >2500 A/Memphis/102/72(H3N2) 10 20 A/Tokyo/6/73(H3N2) 5 40 A/Kumamoto/55/76(H3N2) 20 80 A/Texas/1/77(H3N2) 5 80 A/Yamanashi/2/77(H3N2) 2.5 40 A/Bangkok/1/79(H3N2) 2.5 20 A/Duck/Alba/35/76(H1N1) 10 10 A/Duck/Hong Kong/7/75(H3N2) 1.25 20 A/Duck/Hong Kong/24/76(H3N2) 10 640 A/ duck/Hokkaido/5/77(H3N2) 2.5 20 A/ duck/Hokkaido/8/80(H3N8) 2.5 10 A/Duck/Hong Kong/23/76(H5N3) 1.25 20 A/Hog/Iowa/15/30(H1N1) 1.25 5 A/Pig/Colorado/1/77(H3N2) 320 >2500 A/pig/Hong Kong/126/82(H3N2) 1.25 40

As shown in Table 2, Sample 1, it was found that among the investigated influenza viruses (viruses isolated from humans, poultry, or pigs), there was no response to influenza viruses other than A/pig/Colorado/1/77 (H3N2). The virus exhibits erythrocyte anticoagulant activity at very low concentrations. On the other hand, sample 2 was found to exhibit erythrocyte anticoagulant activity at a low concentration against viruses other than A/Memphis/1/71 and A/pig/Colorado/1/77 (H3N2).

From the above results, it was found that the samples 1 and 2 were adsorbable to the wide-type influenza virus.

(3) The type and content of sialic acid molecules contained in sample 1 and sample 2

It is known that influenza virus recognizes and binds to a specific sugar chain containing sialic acid. Therefore, investigate the molecular species and content of sialic acid in bird's nest by the following method (referring to Hara, S., Yamaguchi, M., Takemori, Y., Nakamura, M., Ohkura, Y.,: by using fluorescent detection High-sensitivity determination of N-acetyl- and N-glycolylneuraminic acid in human serum and urine and mouse serum by reverse d-phase liquid chromatography. Journal of Chromatography, 377, 111-119 (1980), Hara , S., Takemori, Y., Yamaguchi, M., Nakamura, M., Ohkura, Y.: Fluorescent high-performance liquid chromatography of N-acetyl- and N-glycolylceraminoglycolic acids and their use in humans and animals Application of microassays in serum. Analytical Biochemistry, 164, 138-146 (1987)).

That is to say, each sample was heated in 20 μL of 2M acetic acid at 80°C for 3 hours, and after the glycosides of hydrolyzed sialic acid were combined, water was added to the fluorescent reagent (sodium bisulfate 15.7 mg, 2-mercaptoethanol 350 μL and 20 μL of diamino 4,5 methylenedioxybenzene 2HCl (prepared by adding 5 mL of water to 7.9 mg of DMB, Tongren Chemical), and heated at 50° C. for 2.5 hours in the dark.

Of this reaction solution, the fluorescent dielectric of sialic acid was separated by HPLC using 10 μL of COSMOSIL/COSMOGEL karam (trade name, manufactured by NACALAI TESQUE Co., Ltd.), and was separated with a spectrofluorophotometer (trade name '650-10S' manufactured by Hitachi). detection. The results are shown in Fig. 11 .

As shown in FIG. 11 , it was found that both Sample 1 and Sample 2 contained sialic acid, and N-acetylneuraminic acid (NeuAc) was the main molecular species. In addition, it was found that N-glycolylneuraminic acid (NeuGc) was contained in a small ratio. In addition, the N-acetylneuraminic acid content of sample 1 (12.25%) was about twice higher than that of sample 2 (6.25%), and the N-glycolylneuraminic acid content in sample 1 was 0.41%. 0.09% in sample 2.

According to the results, the sialic acid contained in samples 1 and 2 is very similar to the molecular species of human sialic acid, and it is suggested that the protein, peptide or fat molecule containing these sialic acid is a component of influenza virus binding.

In addition, although sample 1 was recognized to have higher influenza virus-binding activity and infection-inhibiting activity than sample 2, this fact is closely related to the fact that sample 1 has a higher sialic acid content than sample 2 , suggesting that the sialic acid-containing molecule in the sample has anti-infective activity.

(4) Investigate the binding of influenza virus to glycopeptides separated by SDS-acrylamide gel electrophoresis (SDS-PAGE) by the following method (see Takashi Suzuki, Mikiko Tsukimoto, Masato Kobayashi, Akira Yamada, Yoshihiro Kawaoka, Robert G. Webster, Yasuo Suzuki: Influenza A virus-bound sialoglycoprotein and antiviral neuraminidase in plasma of various animals. Journal of General Filtration Microbiology, 75, 1769-1774 (1994)).

That is, sample preparation buffer for SDS-PAGE (containing 2% SDS, 10% glycerol, 0.001% bromophenol blue, 0.0625M triple buffer, pH6.8) dilution. Each sample was treated in a boiling water bath for 5 minutes, and then separated by SDS-polyacrylamide (SDS-PSGE plate: trade name 'ET-1020L', manufactured by Art Corporation) at a concentration of 10 to 20% under non-reducing conditions.

The glycopeptide developed into a gel was replicated (applied at 2 mA/cm for 30 minutes) to a polyvinylidene fluoride (PVDF) membrane (manufactured by Daiichi Chemical Co., Ltd.), and 5% bovine blood albumin (BSA)-PBS solution (0.2 mL/cm), inhibited at 4°C for 15 hours. After this PVDF membrane was washed five times with PBS, the influenza virus-0.25% BSA-PBS suspension prepared in 2HAU was added, and in order to avoid the influence of viral neuraminidase, shake steadily at 4°C for 15 Hour. Then, the virus suspension was removed, the PVDF membrane was washed five times with PBS, anti-influenza virus antibody was added, and shaken at 4° C. for 2 hours. Remove the antibody solution, wash the PVDF membrane five times with PBS, add a 0.25% BSA-PBS solution of ABC (peroxidase) Kit (trade name, Victor Laboratories Co., Ltd.) of the VECTASTAIN Kit, and heat Shake for 2 hours. After this PVDF membrane was washed five times with PBS, 200 μL of acetonitrile solution of 110 mM-4-chloro-1-naphthol in 10 mL of 0.1 M acetic acid (pH 6.0), 60 mM N,N-di Ethyl-p-phenylenediamine-dihydrochloride acetonitrile solution 200 μL, 31% hydrogen peroxide solution 1 μL mixture of the three) was investigated for virus binding. The results are shown in Fig. 12 .

As shown in FIG. 12, it can be confirmed that both sample 1 and sample 2 are combined with influenza virus (A/Aichi/2/68 (H3N2), A/Memphis/1/71 (H3N2)). belt (the belt indicated by the arrow in the figure). On the other hand, since the band bound to the virus could not be confirmed in the control experiment (virus (-)) in which the virus was not added and the other procedures were treated in the same manner, it can be considered that the above band is a glycopeptide that specifically binds to the virus. . In addition, although the degree of staining of the band by Coomassie Brilliant Blue (CBB) staining (which can stain proteins or peptides) is almost the same in Samples 1 and 2, the binding to the virus was found to be stronger in Sample 1 than in Sample 2. , and there are many types. From these results, it was found that in sample 1, glycopeptides containing sialic acid bound to influenza virus were more abundant than in sample 2.

The virus-trapping composition of the present invention has high stability because it contains food-derived components as its main component, and can be used as a virus infection prevention agent because it has adsorption properties for various types of viruses. In addition, by delivering the present virus-capturing composition from the teat 11 of the teat device 10 into the mouth of the infant, virus infection of the infant can be prevented.

Claims (17)

1. A pacifier device, characterized in that, Equipped with: a pacifier, a pacifier holding body for holding the pacifier, and a cover that snaps onto the pacifier holding body; A medicament container part is arranged inside the cover, the medicament is filled in it, and one side of the nipple is covered by a film; The pacifier holder is provided with a rupture portion, which punctures the film when the cover is engaged with the pacifier holder. 2. The teat device of claim 1, wherein: The nipple holder is provided with a liquid-permeable body extending into the nipple, The rupture of the teat holder consists of protrusions piercing the film. 3. The pacifier device according to claim 1, wherein the pacifier holder is provided with external threads, and the cap is provided with internal threads engaged with the external threads. 4. The pacifier device according to claim 2, wherein the liquid permeable body is composed of a plate-shaped body abutting against the film of the medicine container portion and a rod-shaped body extending from the plate-shaped body toward the pacifier. 5. The pacifier device according to claim 4, wherein an opening is provided in the plate-shaped body of the liquid-permeable body, and the protrusion protrudes from the pacifier side through the opening toward the drug container side. 6. The teat device according to claim 1, wherein the medicine container portion is constituted by a medicine container provided in the cap. 7. The pacifier device according to claim 1, wherein the drug container portion is formed by a region in the cap defined by the thin film. 8. The teat device of claim 1, wherein: The pacifier holding body has a communication space communicating with the inside of the pacifier, This communication space is provided on the side of the medicine container part and is covered by a partition wall having a communication port. 9. The pacifier device according to claim 8, wherein the rupture portion of the pacifier holder is constituted by an end portion of the partition wall. 10. The teat device according to claim 8, wherein a one-way valve for allowing the medicine to flow from the medicine container portion to the teat holder is provided on the opening of the partition wall. 11. A pacifier device characterized in that, A pacifier, a pacifier holding body that holds the pacifier and has a container receiving portion communicating with one side of the pacifier, and a cover that is swingably mounted on the pacifier holding body and covers the container receiving portion, A drug container is arranged in the container housing portion, and the drug container is filled therein, and has an opening on the nipple side. 12. The teat assembly of claim 11 wherein, A cylindrical guide protruding toward the teat side is provided on the container receiving part, The medicine container has a discharge port inserted into the cylindrical guide. 13. The teat assembly of claim 12, wherein: The medicament container can be freely removed from the container accommodating part, An engaging rib is provided on the lid, and engages with the cylinder guide of the container accommodating part. 14. The teat assembly of claim 12, wherein: The medicament container is made of soft material and is fixed in the container accommodating part, A squeeze part for squeezing the medicine container is provided on the cover. 15. The teat device according to claim 1 or 11, wherein the drug contains xylitol. 16. The teat device according to claim 1 or 11, wherein the medicine contains a virus trapping composition. 17. The teat device according to claim 16, wherein the virus trapping composition contains a water extract of bird's nest and/or an enzyme-treated bird's nest as an active ingredient.

Images